Tesis doctoral de Ceres Fernández Rozadilla
Summary: genomics and pharmacogenomics of colorectal cancer. heritability in colorectal cancer (crc) predisposition has been estimated to be around 35% by twin studies. Although ¿ 5% of this proportion may be explained by high-penetrance mutations, and an additional 7% is thought to be due to the presence of a combination of some of the already-described 16 susceptibility snps, there is still a significant fraction of crc susceptibility that remains unexplained. on the other hand, there is also considerable variation in the way crc patients respond to chemotherapy. Besides, the fact that most drugs used in crc treatment have narrow therapeutic ranges results in the frequent development of adverse drug reactions (adrs). Hence, the identification of the genetic variation modulating this outcome would be most helpful in both the individualisation of the treatment and the reduction of health costs. thus, this phd work has had two main aims: the search for new crc susceptibility variants that could help explain at least part of the missing heritability, andd the analysis of the genetic variation underlying the differences in toxic responses of crc patients treated with chemotherapy.
Datos académicos de la tesis doctoral «Genomics and pharmacogenomics of colorectal cancer«
- Título de la tesis: Genomics and pharmacogenomics of colorectal cancer
- Autor: Ceres Fernández Rozadilla
- Universidad: Santiago de compostela
- Fecha de lectura de la tesis: 22/07/2011
Dirección y tribunal
- Director de la tesis
- Clara María Ruíz Ponte
- Tribunal
- Presidente del tribunal: fernando Dominguez puente
- montserrat Baiget bastús (vocal)
- sergi Castellvi bel (vocal)
- jean-baptiste Cazier (vocal)